Impact of guideline therapy on survival of patients with stage I-III epithelioid mesothelioma.

"Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1334/coif). N.S.L. serves as an unpaid editorial board member of Journal of Thoracic Disease from September 2023 to August 2025. M.F.B. serves as an unpaid editorial board member of Journal of Thoracic Disease from October 2022 to September 2024. L.M.B. has received grant funding from the United States Department of Veterans Affairs, the National Institutes of Health, and the Chan Zuckerberg Institute. She has received royalties from Bristol Squibb Myers, and consulting fees from Genentech and Johnson & Johnson, as well as speaker honoraria from the International Lung Cancer Congress. None of these activities are related to the topic of this manuscript. The other authors have no conflicts of interest to declare."

"Funding: None."